Targeted therapy in npm1-mutated aml: knowns and unknowns

HIGHLIGHTS

• who: Rong Wang et al. from the University of Texas MD Anderson Cancer Center, United States have published the research: Targeted therapy in NPM1-mutated AML: Knowns and unknowns, in the Journal: (JOURNAL) of October/18,/2021
• what: This analysis demonstrated that venetoclax plus HMAs significantly reduced the risk of death and achieved a higher CR rate when compared with standard IC or HMAs .
• how: The aforementioned results indicated that PD-L1 might be a potential therapeutic target in NPM1-mutated AML.
• future: Eltanexor seems to be a prospective drug and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.